In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.

Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, ...

Xlear Inc., of Salt Lake City filed a petition in U.S. district court that could terminate the Federal Trade Commission’s ...

Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in ...

Cue Biopharma Inc. has received pre-IND feedback from the FDA to discuss the proposed development plan for CUE-401, its lead ...

At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers ...

Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations ...

Australia’s largest health insurance company, Medibank Private Ltd., is the first to reimburse for psychedelic treatment in Australia, funding Emyria Ltd.’s MDMA (3,4-methylenedioxy-methamphetamine) ...

Ophthalmology company Polyactiva Pty Ltd closed a AU$40 million (US$25 million) series C round to advance late-stage clinical trials in the U.S. of its lead candidate, PA-5108.